Targeting signaling pathways with small molecules to treat autoimmune disorders. (Q37755216)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477590%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Targeting signaling pathways with small molecules to treat autoimmune disorders (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477590%20AND%20SRC:MED&resulttype=core&format=json

Bożena Kamińska-Kaczmarek

2 February 2020

author

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477590%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Karolina Swiatek-Machado

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477590%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

1 January 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477590%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Clinical Immunology

2 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477590%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477590%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477590%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

93-112

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477590%20AND%20SRC:MED&resulttype=core&format=json

T-cell-mediated signalling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

APC-derived cytokines and T cell polarization in autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Macrophages in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

The immunological and genetic basis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Immunotherapy of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Psoriasis: dysregulation of innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Psoriasis: emerging therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

NF-kappaB: a key role in inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

MAP kinase kinase kinases and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Tumor necrosis factor alpha gene regulation: enhancement of C/EBPbeta-induced activation by c-Jun

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Role of nitric oxide and reactive oxygen species in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

CEP-11004, an inhibitor of the SAPK/JNK pathway, reduces TNF-alpha release from lipopolysaccharide-treated cells and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

R-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

CNI-1493, an inhibitor of proinflammatory cytokines, retards cartilage destruction in rats with collagen induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Inhibition of RICK/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Molecular mechanisms of neuroprotective action of immunosuppressants--facts and hypotheses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

A novel mechanism of FK506-mediated neuroprotection: downregulation of cytokine expression in glial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Cyclosporine A enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS. Paradoxical proinflammatory effect on the microvascular endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Anti-arthritic properties of FK506 on collagen-induced arthritis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Pimecrolimus versus topical corticosteroids in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Signaling through the JAK/STAT pathway, recent advances and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

The role of STATs in inflammation and inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

IFNs and STATs in innate immunity to microorganisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

The role of Stat5a and Stat5b in signaling by IL-2 family cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Interleukin-6 trans-signalling in chronic inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

The role of Tyk2, Stat1 and Stat4 in LPS-induced endotoxin signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Partial impairment of cytokine responses in Tyk2-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

An interferon-gamma-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-gamma and lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

A new modality for immunosuppression: targeting the JAK/STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Targeting JAK3 and BTK tyrosine kinases with rationally-designed inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

CXCL12 and C5a trigger cell migration via a PAK1/2-p38α MAPK-MAPKAP-K2-HSP27 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

Anti-inflammatory effects of a new tumour necrosis factor-alpha (TNF-alpha) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.4.1.93

21 January 2018

Identifiers

DOI

10.1586/1744666X.4.1.93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477590%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20477590%20AND%20SRC:MED&resulttype=core&format=json